StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 22 Jun 2026 16:33:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: Shah Rajeev M. http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Shah+Rajeev+M./26673609.html si-local-file:///var/storage/secattach/20260622/26673609.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Shah+Rajeev+M./26673609.html Mon, 22 Jun 2026 16:33:00 -0400 ACRV O.50727910 Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: Shah Rajeev M. http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Shah+Rajeev+M./26673609.html si-local-file:///var/storage/secattach/20260622/26673609.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Shah+Rajeev+M./26673609.html Mon, 22 Jun 2026 16:33:00 -0400 ACRV O.50727910 Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: TOMSICEK MICHAEL JOHN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+TOMSICEK+MICHAEL+JOHN/26673230.html si-local-file:///var/storage/secattach/20260622/26673230.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+TOMSICEK+MICHAEL+JOHN/26673230.html Mon, 22 Jun 2026 16:14:00 -0400 ACRV O.50727910 Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: TOMSICEK MICHAEL JOHN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+TOMSICEK+MICHAEL+JOHN/26673230.html si-local-file:///var/storage/secattach/20260622/26673230.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+TOMSICEK+MICHAEL+JOHN/26673230.html Mon, 22 Jun 2026 16:14:00 -0400 ACRV O.50727910 Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: Shacham Sharon http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Shacham+Sharon/26673184.html si-local-file:///var/storage/secattach/20260622/26673184.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Shacham+Sharon/26673184.html Mon, 22 Jun 2026 16:13:00 -0400 ACRV O.50727910 Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: Shacham Sharon http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Shacham+Sharon/26673184.html si-local-file:///var/storage/secattach/20260622/26673184.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Shacham+Sharon/26673184.html Mon, 22 Jun 2026 16:13:00 -0400 ACRV O.50727910 Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: Palani Santhosh http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Palani+Santhosh/26673129.html si-local-file:///var/storage/secattach/20260622/26673129.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Palani+Santhosh/26673129.html Mon, 22 Jun 2026 16:12:00 -0400 ACRV O.50727910 Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: Palani Santhosh http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Palani+Santhosh/26673129.html si-local-file:///var/storage/secattach/20260622/26673129.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Palani+Santhosh/26673129.html Mon, 22 Jun 2026 16:12:00 -0400 ACRV O.50727910 Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: Magovcevic-Liebisch Ivana http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Magovcevic-Liebisch+Ivana/26673100.html si-local-file:///var/storage/secattach/20260622/26673100.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Magovcevic-Liebisch+Ivana/26673100.html Mon, 22 Jun 2026 16:10:00 -0400 ACRV O.50727910 Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: Magovcevic-Liebisch Ivana http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Magovcevic-Liebisch+Ivana/26673100.html si-local-file:///var/storage/secattach/20260622/26673100.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+Magovcevic-Liebisch+Ivana/26673100.html Mon, 22 Jun 2026 16:10:00 -0400 ACRV O.50727910 Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: DiRocco Derek http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+DiRocco+Derek/26673069.html si-local-file:///var/storage/secattach/20260622/26673069.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+DiRocco+Derek/26673069.html Mon, 22 Jun 2026 16:09:00 -0400 ACRV O.50727910 Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: DiRocco Derek http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+DiRocco+Derek/26673069.html si-local-file:///var/storage/secattach/20260622/26673069.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+DiRocco+Derek/26673069.html Mon, 22 Jun 2026 16:09:00 -0400 ACRV O.50727910 Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: BAUM CHARLES M http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+BAUM+CHARLES+M/26673049.html si-local-file:///var/storage/secattach/20260622/26673049.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+BAUM+CHARLES+M/26673049.html Mon, 22 Jun 2026 16:08:00 -0400 ACRV O.50727910 Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: BAUM CHARLES M http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+BAUM+CHARLES+M/26673049.html si-local-file:///var/storage/secattach/20260622/26673049.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17++Filed+by%3A+BAUM+CHARLES+M/26673049.html Mon, 22 Jun 2026 16:08:00 -0400 ACRV O.50727910 Form 8-K Acrivon Therapeutics, For: Jun 17 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17/26661031.html si-local-file:///var/storage/secattach/20260617/26661031.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17/26661031.html Wed, 17 Jun 2026 17:28:00 -0400 ACRV O.50727910 Form 8-K Acrivon Therapeutics, For: Jun 17 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17/26661031.html si-local-file:///var/storage/secattach/20260617/26661031.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17/26661031.html Wed, 17 Jun 2026 17:28:00 -0400 ACRV O.50727910 Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens Amid Acquisition by GSK http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens Amid Acquisition by GSK http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens Amid Acquisition by GSK http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens Amid Acquisition by GSK http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens Amid Acquisition by GSK http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY Form 4 Acrivon Therapeutics, For: May 21 Filed by: Blume-Jensen Peter http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+21++Filed+by%3A+Blume-Jensen+Peter/26550009.html si-local-file:///var/storage/secattach/20260526/26550009.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+21++Filed+by%3A+Blume-Jensen+Peter/26550009.html Tue, 26 May 2026 16:09:00 -0400 ACRV O.50727910 Form 4 Acrivon Therapeutics, For: May 21 Filed by: Blume-Jensen Peter http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+21++Filed+by%3A+Blume-Jensen+Peter/26550009.html si-local-file:///var/storage/secattach/20260526/26550009.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+21++Filed+by%3A+Blume-Jensen+Peter/26550009.html Tue, 26 May 2026 16:09:00 -0400 ACRV O.50727910 Form DEFA14A Acrivon Therapeutics, http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Acrivon+Therapeutics%2C++++++++++++++++/26541515.html si-local-file:///var/storage/secattach/20260522/26541515.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Acrivon+Therapeutics%2C++++++++++++++++/26541515.html Fri, 22 May 2026 16:06:00 -0400 ACRV O.50727910 Form DEFA14A Acrivon Therapeutics, http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Acrivon+Therapeutics%2C++++++++++++++++/26541515.html si-local-file:///var/storage/secattach/20260522/26541515.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Acrivon+Therapeutics%2C++++++++++++++++/26541515.html Fri, 22 May 2026 16:06:00 -0400 ACRV O.50727910